ATS 2025
Delivering Adaptive Approaches to Pulmonary Sarcoidosis
Xentria presents an overview of the journey XTMAB-16, its lead investigational therapy, with a poster presentation at the American Thoracic Society (ATS) Respiratory Summit 2025. XTMAB-16 is a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNFα), a proinflammatory cytokine involved in sarcoidosis. The poster displays the roadmap advancing XTMAB-16 along the drug development journey. Xentria provided an overview of the unmet need in sarcoidosis and how XTMAB-16 is hoping to be a solution for patients living with this rare disease.
Key findings to date:
- Implementation of model-informed dosing strategies to mitigate development risk in sarcoidosis, a challenging rare disease that is difficult to treat and diagnose
-
Nonclinical data demonstrating ability for XTMAB-16 to prevent granuloma formation in an exposure-dependent fashion in vitro
- XTMAB-16 showed a superior dose effect to the standard of care, corticosteroids, at doses comparable to therapeutic and supra-therapeutic doses; with supra-therapeutic dose of steroids being toxic and infeasible
- Creation of a stage-gated clinical development plan aiming to align with agency as well as patient needs
About XTMAB-16
XTMAB-16 is novel biologic developed by Xentria to address the unmet medical need for patients with sarcoidosis, a rare inflammatory disease that affects multiple organs in the body. XTMAB-16 is a monoclonal antibody designed to suppress the inflammatory pathways promotion of sarcoidosis granuloma formation. No TNF-α inhibitor is currently approved for the treatment of sarcoidosis. Extensive analyses have been conducted to demonstrate the physio-chemical properties and pharmacology of XTMAB-16 as a TNFα inhibitor. The clinical study of this effect remains ongoing.
XTMAB-16 is not available for sale in the United States. Future commercial use will depend on successful clinical trials and regulatory review and approval.
About Sarcoidosis
Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the presence of noncaseating epithelioid granulomas, accompanied by infiltration of mononuclear cells and destruction of microarchitecture. The disease can affect the skin, eyes, heart, and central nervous system, and >90% of cases involve the lungs. While medications for systemic organ involvement often control this disease, some patients fail to respond to initial treatments and require additional targeted therapy, resulting in significant costs and treatment burdens. This disease presents a significant unmet medical need and a very important area of research and development for Xentria.
American Thoracic Society (ATS)
Respiratory Summit
Date: May 16-17, 2025
Location: San Francisco
Presentation: Abstract poster